

August 19, 2024

# Q1FY25 Result Update

■ Change in Estimates | ☑ Target | ■ Reco

#### **Change in Estimates**

	Cur	rent	Prev	/ious
	FY25E FY26E		FY25E	FY26E
Rating	В	UY	В	UY
Target Price	7	00	6	00
Sales (Rs. m)	15,905	19,497	15,905	19,497
% Chng.	-	-		
EBITDA (Rs. m)	4,621	6,375	4,621	6,375
% Chng.	-	-		
EPS (Rs.)	23.9	33.6	23.9	33.6
% Chng.	-	-		

#### Key Financials - Consolidated

Y/e Mar	FY23	FY24	FY25E	FY26E
Sales (Rs. m)	3,624	5,648	15,905	19,497
EBITDA (Rs. m)	642	1,173	4,621	6,375
Margin (%)	17.7	20.8	29.1	32.7
PAT (Rs. m)	14	709	3,494	4,922
EPS (Rs.)	0.1	4.8	23.9	33.6
Gr. (%)	(94.4)	4,727.9	392.6	40.9
DPS (Rs.)	1.0	1.0	1.5	2.0
Yield (%)	0.2	0.2	0.3	0.3
RoE (%)	0.1	2.4	10.6	13.4
RoCE (%)	1.6	3.1	12.3	15.4
EV/Sales (x)	24.2	15.7	5.6	4.5
EV/EBITDA (x)	136.9	75.7	19.3	13.9
PE (x)	5,860.9	121.4	24.6	17.5
P/BV (x)	3.0	2.8	2.5	2.2

Key Data	SUNT.BO   SRIN IN
52-W High / Low	Rs.699 / Rs.351
Sensex / Nifty	80,437 / 24,541
Market Cap	Rs.86bn/ \$ 1,026m
Shares Outstanding	146m
3M Avg. Daily Value	Rs.604.11m

#### **Shareholding Pattern (%)**

Promoter's	63.24
Foreign	18.53
Domestic Institution	9.29
Public & Others	8.94
Promoter Pledge (Rs bn)	-

#### Stock Performance (%)

	1M	6M	12M
Absolute	(6.7)	27.4	62.3
Relative	(6.4)	14.1	31.9

#### Param Desai

paramdesai@plindia.com | 91-22-66322259

Sanketa Kohale

sanketakohale@plindia.com | 91-22-66322426

# Sunteck Realty (SRIN IN)

# Rating: BUY | CMP: Rs588 | TP: Rs700

# Strong quarter; new launches hold key

#### **Quick Pointers:**

- Reiterated pre-sales guidance at +30% in FY25; GDV of Rs. 50bn to launch.
- Expect to book revenues from 4<sup>th</sup> Avenue city in FY25

Sunteck Reality (SRIN) reported healthy pre-sales (+30% YoY) and collections (19% YoY) in Q1. SRIN's proven ability to market ultra-luxury projects, aggressive and multi-pronged land acquisition capabilities in various micro markets across Mumbai Metropolitan Region (MMR) is an interesting play on Mumbai's high value real estate market. We expect company's pre-sales to grow +25% CAGR over FY24-26E aided by ongoing projects and strong new launches pipeline including new Dubai JV project. Further given likely strong cash flow generation and JV with IFC, we see SRIN to step up new project additions which will be a key catalyst for stock performance. Adoption of asset light model has enabled the company to acquire scale without straining its balance sheet. Maintain 'Buy' rating with a revised TP of Rs. 700/share as we incorporate Dubai project.


- Naigaon (MaxxWorld) and BKC projects recognition aided revenues: Operationally, SRIN reported EBITDA of Rs 314mn vs Rs 1.6bn in Q4FY24; QoQ declined was largely due to Naigaon project's revenue recognition. Consolidated revenues grew robust by 348% YoY to Rs. 3.2bn. PAT came in at Rs. 228mn, vs Rs. 1bn QoQ and loss of Rs. 67mn YoY. During Q1, revenue got recognized from its Naigaon project- Max world phase 1 and BKC projects During the quarter, the company continued to improve its net cash position by Rs. 310mn to Rs. 390mn.
- Healthy pre-sales and collections: SRIN's pre-sales improved 30% YoY to Rs 5bn (down 26% QoQ); aided by all existing projects. BKC projects contributed Rs1.1bn to total pre-sales while high mid-income projects (Sunteck City, Beach residencies, Sky Park projects) contributed 46% (Rs. 2.3bn) to total pre-sales. During Q1, average realization increased 5% QoQ to Rs. 11,265 psf. Collections grew strong by 19% YoY and 15% QoQ to Rs3.4bn in Q1; aided by OC received for Naigaon project.
- Key con-call takeaways: (1) pre-sales guidance Reiterated 32-35% growth in presales for FY25. Mgmt indicated that height approvals for additional FSI utilization are being sought for the existing development at Sunteck City Avenue 2 in ODC. (2) Combined GDV of Rs. 50bn to launch for FY25 -Plans to launch a new phase in Sunteck World Naigaon, new phase at Mira road, new phase at 5th avenue in ODC, 1-2 towers in SBR Vasai and 1-2 towers in Crescent Park at Kalyan. (3) Revenue recognition in FY25 Sunteck City 4<sup>th</sup> Avenue is nearing completion and expect to book revenues in FY25 with higher margins due to better realizations. Sunteck Maxx World also partially to get recognized in FY25. (4) Dubai project - The project will be executed by 100% Sunteck subsidiary at 50% profit share where partner company will be constructing the premium residential apartments with a total cost and GDV of Rs. 20bn and 90bn; respectively; of which SRIN has spent Rs. 2.5bn with no incremental capex required. (5) Nepean sea road project is progressing well at an advanced stages of clearances, tenant vacating completed and design underway for a Q4FY25 or Q1FY26 launch with a GDV of Rs. 25bn. (6) Unsold Inventory - SRIN has ready-to-move-in unsold inventory of Rs. 12bn at BKC, while ongoing projects unsold inventory valued at Rs. 16-17bn. (7) Exploring 3-4 opportunities in its BD activity. Also in process of evaluating and finalizing the project through IFC platform.

Exhibit 1: Q1FY25 Result Overview	(Rs mn) – Operationally Healthy quarter

Y/e March	1QFY25	1QFY24	YoY gr. (%)	4QFY24	QoQ gr. (%)	FY25E	FY24	YoY gr. (%)
Net Sales	3,163	706	348.2	4,269	(25.9)	15,905	5,648	181.6
COGS	2,316	302	667.5	2,121	9.2	8,709	2,353	270.2
% of Net Sales	73.2	42.8		49.7		54.8	41.6	
Employee Cost	235	216	9.1	230	2.5	1,083	903	20.0
% of Net Sales	7.4	30.5		5.4		19.2	16.0	
Other Expenses	298	263	13.2	384	(22.5)	1,492	1,220	22.3
% of Net Sales	9.4	37.2		9.0		26.4	21.6	
Total	2,849	780	265.1	2,735	4.2	11,285	4,476	152.1
EBITDA	314	(75)	(521.0)	1,534	(79.5)	4,621	1,173	294.0
Margins (%)	9.9	(10.6)		35.9		29.1	20.8	
Other Income	117	178	(34.2)	81	44.8	600	555	8.2
Interest	103	173	(40.7)	182	(43.4)	492	684	(28.0)
Depreciation	34	18	89.0	31	8.2	110	95	15.4
РВТ	295	(87)	(438.5)	1,402	(79.0)	4,618	949	386.8
Тах	70	(27)	(360.6)	386	(81.8)	1,155	240	380.2
Tax rate %	23.9	31.0		27.5		25.0	25.3	
РАТ	224	(60)	(473.5)	1,016	(77.9)	3,464	708	389.0
Share in (loss)/profit of associate	3	(7)		(3)		30	1	
Reported PAT	228	(67)	(438.2)	1,013	(77.5)	3,494	709	392.6


Source: Company, PL

## Exhibit 2: Healthy pre-sales led by high mid-income projects



Source: Company, PL

## Exhibit 3: Collections improved by 19% YoY and 16% QoQ



Source: Company, PL

# Exhibit 4: Pre-sales and collections break up (in mn)

Segment	Projects -	Pre-sales (~Rs i	n mn)	Collections (~Rs in mn)	
		Q1FY25	FY24	Q1FY25	FY24
Uber Luxury	Signature, Signia	1,100	2,450	1,140	2,200
High Mid-income	Sunteck City, SBR, Sky Park	2,320	9,680	750	4,130
Low Mid-Income	Sunteck World	1,210	4,870	1,360	1,770
Others		380	2,150	170	4,250
Total		5,010	19,150	3,420	12,350

Source: Company, PL

# Exhibit 5: NAV valuations Summary

	(Rs mn)	% of total	NAV per share
Residential	81,050	79%	553
Commercial (Sell)	15,301	17%	104
Commercial (Lease)	6,005	7%	41
Gross NAV	102,356	100%	700
Add: Cash	3,858		26
Less: Gross Debt	-3,749		-26
Net NAV	102,465		
Outstanding shares (m)	146.5		
NAV per share	700		

Source: Company, PL

FY25E

FY26E

FY24

# **Financials**

## Income Statement (Rs m)

Y/e Mar	FY23	FY24	FY25E	FY26E	Y/e N
Net Revenues	3,624	5,648	15,905	19,497	Non-C
YoY gr. (%)	(29.4)	55.8	181.6	22.6	
Cost of Goods Sold	1,276	2,353	8,709	10,051	Gross
Gross Profit	2,348	3,296	7,196	9,446	Tang
Margin (%)	64.8	58.4	45.2	48.4	Intan
Employee Cost	690	903	1,083	1,300	
Other Expenses	-	-	-	-	Acc: E
					Tang
EBITDA	642	1,173	4,621	6,375	Intan
YoY gr. (%)	(32.7)	82.8	294.0	38.0	
Margin (%)	17.7	20.8	29.1	32.7	Net fix
					Tang
Depreciation and Amortization	92	95	110	120	Intan
EBIT	549	1,078	4,511	6,255	Capita
Margin (%)	15.2	19.1	28.4	32.1	Goodv
					Non-C
Net Interest	859	684	492	492	Net De
Other Income	284	555	600	760	Other
Profit Before Tax	(25)	949	4,618	6,523	Curre
Margin (%)	(0.7)	16.8	29.0	33.5	Inves
					Inver
Total Tax	31	240	1,155	1,631	Trade
Effective tax rate (%)	(122.0)	25.3	25.0	25.0	Cash
					Othe
Profit after tax	(56)	708	3,464	4,892	Total
Minority interest	-	-	-	-	
Share Profit from Associate	70	1	30	30	Equity
					Equit
Adjusted PAT	14	709	3,494	4,922	Othe
YoY gr. (%)	(94.4)	4,934.3	392.6	40.9	Total
Margin (%)	0.4	12.6	22.0	25.2	
Extra Ord. Income / (Exp)	-	-	-	-	Non-C
					Long
Reported PAT	14	709	3,494	4,922	Provi
YoY gr. (%)	(94.4)	4,934.3	392.6	40.9	Othe
Margin (%)	0.4	12.6	22.0	25.2	•
					Curre
Other Comprehensive Income	-	-	-	-	ST D
Total Comprehensive Income	14	709	3,494	4,922	Trade
Equity Shares O/s (m)	140	146	146	146	Othe
EPS (Rs)	0.1	4.8	23.9	33.6	Total

## Balance Sheet Abstract (Rs m) Y/e Mar FY23

T/e War	F123	F124	FIZJE	FIZOE
Non-Current Assets				
Gross Block	1,768	5,255	5,355	5,455
Tangibles	1,768	5,255	5,355	5,455
Intangibles	-	-	-	-
Acc: Dep / Amortization	279	374	484	604
Tangibles	279	374	484	604
Intangibles	-	-	-	-
Net fixed assets	1,490	4,881	4,871	4,851
Tangibles	1,490	4,881	4,871	4,851
Intangibles	-	-	-	-
Capital Work In Progress	1,012	183	183	183
Goodwill	14	25	25	25
Non-Current Investments	4,711	5,204	5,786	6,484
Net Deferred tax assets	334	400	400	400
Other Non-Current Assets	-	-	-	-
Current Assets				
Investments	-	-	-	-
Inventories	57,251	59,663	62,721	65,626
Trade receivables	1,496	2,925	3,725	4,725
Cash & Bank Balance	1,582	1,058	531	1,398
Other Current Assets	4,688	4,838	5,000	5,000
Total Assets	72,243	78,778	82,843	88,293
Equity				
Equity Share Capital	140	146	146	146
Other Equity	27,738	31,095	34,369	38,998
Total Networth	27,879	31,242	34,516	39,145
Non-Current Liabilities				
Long Term borrowings	4,208	2,507	2,507	2,507
Provisions	-	-	-	-
Other non current liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	2,646	1,243	1,243	1,243
Trade payables	2,114	2,916	3,208	3,528
Other current liabilities	35,731	41,270	41,770	42,270

Source: Company Data, PL Research

Source: Company Data, PL Research

# P

# Cash Flow (Rs m)

Cash Flow (KS III)				
Y/e Mar	FY23	FY24	FY25E	FY26E
РВТ	(25)	949	4,618	6,523
Add. Depreciation	92	95	110	120
Add. Interest	859	684	492	492
Less Financial Other Income	284	555	600	760
Add. Other	(1,261)	(2,142)	70	70
Op. profit before WC changes	(335)	(415)	5,291	7,205
Net Changes-WC	2,986	1,745	(3,811)	(3,782)
Direct tax	(31)	(240)	(1,155)	(1,631)
Net cash from Op. activities	2,620	1,090	325	1,793
Capital expenditures	(1,125)	197	(100)	(100)
Interest / Dividend Income	-	-	-	-
Others	1,288	2,314	-	-
Net Cash from Invt. activities	162	2,511	(100)	(100)
Issue of share cap. / premium	0	6	-	-
Debt changes	(1,015)	(3,105)	-	-
Dividend paid	(140)	(146)	(220)	(293)
Interest paid	(859)	(684)	(492)	(492)
Others	(924)	77	(40)	(40)
Net cash from Fin. activities	(2,939)	(3,852)	(752)	(825)
Net change in cash	(156)	(251)	(527)	867
Free Cash Flow	1,495	1,287	225	1,693

Key Financial Metrics				
Y/e Mar	FY23	FY24	FY25E	FY26E
Per Share(Rs)				
EPS	0.1	4.8	23.9	33.6
CEPS	0.8	5.5	24.6	34.4
BVPS	198.5	213.3	235.6	267.2
FCF	10.6	8.8	1.5	11.6
DPS	1.0	1.0	1.5	2.0
Return Ratio(%)				
RoCE	1.6	3.1	12.3	15.4
ROIC	0.8	1.4	5.5	7.2
RoE	0.1	2.4	10.6	13.4
Balance Sheet				
Net Debt : Equity (x)	0.2	0.1	0.1	0.1
Net Working Capital (Days)	5,703	3,856	1,451	1,251
Valuation(x)				
PER	5,860.9	121.4	24.6	17.5
P/B	3.0	2.8	2.5	2.2
P/CEPS	776.4	107.0	23.9	17.1
EV/EBITDA	136.9	75.7	19.3	13.9
EV/Sales	24.2	15.7	5.6	4.5
Dividend Yield (%)	0.2	0.2	0.3	0.3
Source: Company Data, PL Research				

Source: Company Data, PL Research

## Quarterly Financials (Rs m)

Y/e Mar	Q2FY24	Q3FY24	Q4FY24	Q1FY25
Net Revenue	249	424	4,269	3,163
YoY gr. (%)	8.6	(52.5)	773.4	348.2
Raw Material Expenses	(51)	(28)	2,121	2,316
Gross Profit	300	453	2,148	846
Margin (%)	120.3	106.6	50.3	26.8
EBITDA	(141)	(148)	1,534	314
YoY gr. (%)	148.5	(182.2)	(1,785.7)	(521.0)
Margin (%)	(56.7)	(34.9)	35.9	9.9
Depreciation / Depletion	22	24	31	34
EBIT	(164)	(172)	1,503	280
Margin (%)	(65.6)	(40.6)	35.2	8.9
Net Interest	158	171	182	103
Other Income	113	185	81	117
Profit before Tax	(209)	(158)	1,402	295
Margin (%)	(83.7)	(37.2)	32.9	9.3
Total Tax	(64)	(55)	386	70
Effective tax rate (%)	30.5	34.9	27.5	23.9
Profit after Tax	(145)	(103)	1,016	224
Minority interest	(6)	(6)	3	(3)
Share Profit from Associates	-	-	-	-
Adjusted PAT	(139)	(97)	1,013	228
YoY gr. (%)	39.2	(570.5)	(462.7)	(438.2)
Margin (%)	(55.9)	(22.9)	23.7	7.2
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	(139)	(97)	1,013	228
YoY gr. (%)	39.2	(570.5)	(462.7)	(438.2)
Margin (%)	(55.9)	(22.9)	23.7	7.2
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	(139)	(97)	1,013	228
Avg. Shares O/s (m)	-	-	-	-
EPS (Rs)	(1.0)	(0.7)	6.9	1.6

## **Key Operating Metrics**

Y/e Mar	FY23	FY24	FY25E	FY26E
Real estate revenues	2,908	5,471	15,345	18,780
Lease Rent	94	103	486	643

Source: Company Data, PL Research

# Sunteck Realty

# **Sunteck Realty**

# **Price Chart**



# **Recommendation History**

No.	Date	Rating	TP (Rs.) Share Pr	ice (Rs.)
1	02-Jun-24	BUY	600	471
2	23-Jan-24	BUY	565	452
3	24-Oct-23	BUY	565	436
4	13-Sep-23	BUY	565	397

## Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Apollo Hospitals Enterprise	BUY	7,150	6,516
2	Aster DM Healthcare	BUY	400	368
3	Aurobindo Pharma	Accumulate	1,525	1,462
4	Cipla	Accumulate	1,680	1,575
5	Divi's Laboratories	Accumulate	5,000	4,991
6	Dr. Reddy's Laboratories	Reduce	6,000	6,879
7	Eris Lifesciences	BUY	1,250	1,128
8	Fortis Healthcare	BUY	515	486
9	Glenmark Pharmaceuticals	Reduce	570	1,017
10	HealthCare Global Enterprises	BUY	420	362
11	Indoco Remedies	Accumulate	320	322
12	Ipca Laboratories	Reduce	1,250	1,349
13	J.B. Chemicals & Pharmaceuticals	BUY	2,100	1,930
14	Jupiter Life Line Hospitals	BUY	1,475	1,315
15	Krishna Institute of Medical Sciences	BUY	2,400	2,192
16	Lupin	BUY	2,300	1,994
17	Max Healthcare Institute	BUY	975	916
18	Narayana Hrudayalaya	BUY	1,350	1,218
19	Sun Pharmaceutical Industries	BUY	1,885	1,715
20	Sunteck Realty	BUY	600	471
21	Torrent Pharmaceuticals	Accumulate	3,300	3,162
22	Zydus Lifesciences	Accumulate	1,305	1,301

PL's Recommendation Nomenclature (Absolute Performance)

Buy	:	> 15%
Accumulate	:	5% to 15%
Hold	:	+5% to -5%
Reduce	:	-5% to -15%
Sell	:	< -15%
Not Rated (NR)	:	No specific call on the stock
Under Review (UR)	:	Rating likely to change shortly

# ANALYST CERTIFICATION

#### (Indian Clients)

We/l, Mr. Param Desai- MBA Finance, Ms. Sanketa Kohale- MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

#### (US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

#### DISCLAIMER

#### **Indian Clients**

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai- MBA Finance, Ms. Sanketa Kohale- MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

#### US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

#### Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 <a href="http://www.plindia.com">www.plindia.com</a>